Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Dec;54(12):5180-6.
doi: 10.1128/AAC.01414-09. Epub 2010 Oct 4.

Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia

Affiliations
Randomized Controlled Trial

Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia

Christopher M Rubino et al. Antimicrob Agents Chemother. 2010 Dec.

Abstract

Tigecycline is a new-generation of tetracycline (glycylcyclines) and is active in vitro against bacteria that possess any of the classical genes that confer tetracycline resistance through ribosomal protection or efflux pumps. Herein, tigecycline disposition in patients with community- or hospital-acquired pneumonia was described using a population pharmacokinetic model. Additionally, the influence of covariates, such as body surface area, severity of illness, and clinical laboratory measures, on tigecycline disposition was evaluated. An intravenous loading dose of 100 mg was followed by 50 mg of tigecycline every 12 h. The final population pharmacokinetic model was a two-compartment model with linear elimination and with a relationship between tigecycline clearance and body surface area and creatinine clearance. The model was parameterized using total clearance (CL), the volume of the central compartment, distributional clearance from the central to the peripheral compartment, and volumes of distribution at steady state. Relationships between body surface area and creatinine clearance were identified as significant predictors of interindividual variability on CL. This model will serve as the basis for estimating tigecycline exposure for pharmacokinetic-pharmacodynamic analyses for efficacy and safety among patients with community- or hospital-acquired pneumonia.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Scatter plot of observed versus individual predicted tigecycline concentrations for the final population model for patients with either community- or hospital-acquired pneumonia (A). Scatter plot of individual weighted residuals versus individual predicted tigecycline concentrations for the final population model (B). Note that the solid line represents the line of identity. OBS, observed; PRED, predicted.
FIG. 2.
FIG. 2.
Frequency distribution histograms of mean parameter estimates from analysis of the 50 bootstrap data sets. Note that the vertical line represents the mean estimate from the analysis of the original data set.

Similar articles

Cited by

References

    1. Akaike, H. 1979. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242.
    1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin. Infect. Dis. 44:79-86. - PubMed
    1. Bassett, E. J., M. S. Keith, G. J. Armelagos, D. L. Martin, and A. R. Villnueva. 1980. Tetracycline labeled human bone from ancient Sudanese Nubia. Science 209:1532-1534. - PubMed
    1. Bauer, R. J. 2006. S-ADAPT/MCPEM user's guide: software for pharmacokinetic, pharmacodynamic and population data analysis. Biomedical Simulations Resource, Los Angeles, CA. http://bmsr.usc.edu/Software/ADAPT/SADAPTsoftware.html.
    1. Beal, S. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 2:481-504. - PubMed

Publication types